keyword
MENU ▼
Read by QxMD icon Read
search

Gallium-68

keyword
https://www.readbyqxmd.com/read/28697189/gallium-68-dotatate-pet-ct-is-better-than-ct-in-the-management-of-somatostatin-expressing-tumors-first-experience-in-africa
#1
Ismaheel O Lawal, Kehinde O Ololade, Thabo Lengana, Florette Reyneke, Alfred O Ankrah, Thomas Ebenhan, Mariza Vorster, Mike M Sathekge
OBJECTIVE: In this study we aimed to present our experience on the use of Gallium-68-dotatate with positron emission tomography, computed tomography ((68) Ga-dotatate PET/CT) in the management of neuroendocrine tumors (NET) and other somatostatin expressing tumors. SUBJECTS AND METHODS: We retrospectively reviewed patients with histologically confirmed or biochemically suspected NET and other somatostatin expressing (SSTR) tumors imaged at our department with (68)Ga-dotatate PET/CT...
July 12, 2017: Hellenic Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28685078/-68-ga-psma-pet-ct-for-the-detection-of-bone-metastasis-in-recurrent-prostate-cancer-and-a-psa-level-2-ng-ml-two-case-reports-and-a-literature-review
#2
Lars J Petersen, Julie B Nielsen, Katja Dettmann, Rune V Fisker, Uwe Haberkorn, Louise Stenholt, Helle D Zacho
Localization of prostate cancer recurrence, particularly in the bones, is a major challenge with standard of care imaging in patients with biochemical recurrence following curatively intended treatment. Gallium-68-labeled prostate specific membrane antigen positron emission tomography/computed tomography ((68)Ga-PSMA PET/CT) is a novel and promising method for imaging in prostate cancer. The present study reports two cases of patients with prostate cancer with biochemical recurrence, with evidence of bone metastases on (68)Ga-PSMA PET/CT images and low prostate specific antigen PSA levels (<2 ng/ml) and PSA doubling time >6 months...
July 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28670175/a-comparative-study-of-68-gallium-prostate-specific-membrane-antigen-positron-emission-tomography-computed-tomography-and-magnetic-resonance-imaging-for-lymph-node-staging-in-high-risk-prostate-cancer-patients-an-initial-experience
#3
Manoj Gupta, Partha S Choudhury, Dibyamohan Hazarika, Sudhir Rawal
Lymph node staging plays an important role in planning initial management in nonmetastatic prostate cancer. This article compares the role of (68)Gallium ((68)Ga)-prostate specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) with magnetic resonance imaging (MRI), which is considered the standard staging modality. Out of 39 high-risk prostate cancer patients who underwent (68)Ga-PSMA PET-CT for staging (December 2014-December 2015), 12 patients underwent radical prostatectomy along with ePLND and were included in the analysis...
July 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28649735/diagnostic-sensitivity-of-tc-99m-hynic-psma-spect-ct-in-prostate-carcinoma-a-comparative-analysis-with-ga-68-psma-pet-ct
#4
Ismaheel O Lawal, Alfred O Ankrah, Neo P Mokgoro, Mariza Vorster, Alex Maes, Mike M Sathekge
BACKGROUND: Emerging data from published studies are demonstrating the superiority of Ga-68 PSMA PET/CT imaging in prostate cancer. However, the low yield of the Ge-68/Ga-68 from which Gallium-68 is obtained and fewer installed PET/CT systems compared to the SPECT imaging systems may limit its availability. We, therefore, evaluated in a head-to-head comparison, the diagnostic sensitivity of Ga-68 PSMA PET/CT and Tc-99m PSMA SPECT/CT in patients with prostate cancer. METHODS: A total of 14 patients with histologically confirmed prostate cancer were prospectively recruited to undergo Ga-68 PSMA PET/CT and Tc-99m HYNIC PSMA SPECT/CT...
June 26, 2017: Prostate
https://www.readbyqxmd.com/read/28621567/-68-ga-radiolabeled-aguix-nanoparticles-as-dual-modality-imaging-agents-for-pet-mri-guided-radiation-therapy
#5
Penelope Bouziotis, Dimitris Stellas, Eloïse Thomas, Charles Truillet, Charalampos Tsoukalas, François Lux, Theodoros Tsotakos, Stavros Xanthopoulos, Maria Paravatou-Petsotas, Anastasios Gaitanis, Lia Angela Moulopoulos, Vassilis Koutoulidis, Constantinos D Anagnostopoulos, Olivier Tillement
AIM: The aim of this study was to develop a dual-modality positron emission tomography/magnetic resonance (PET/MR) imaging probe by radiolabeling gadolinium-containing AGuIX derivatives with the positron-emitter Gallium-68 ((68)Ga). MATERIALS & METHODS: AGuIX@NODAGA nanoparticles were labeled with (68)Ga at high efficiency. Tumor accumulation in an appropriate disease model was assessed by ex vivo biodistribution and in vivo PET/MR imaging. RESULTS:  (68)Ga-AGuIX@NODAGA was proven to passively accumulate in U87MG human glioblastoma tumor xenografts...
June 16, 2017: Nanomedicine
https://www.readbyqxmd.com/read/28576423/-pet-ct-and-biochemical-recurrence-of-prostate-adenocarcinoma-added-value-of-68-ga-psma-11-when-18-f-fluorocholine-is-non-contributive
#6
M Gauthé, O Belissant, A Girard, J Zhang Yin, J Ohnona, A-S Cottereau, V Nataf, S Balogova, D Pontvert, T Lebret, B Guillonneau, O Cussenot, J-N Talbot
INTRODUCTION: Since April 201, we have introduced PET/CT using a ligand of prostate-specific membrane antigen labeled with gallium-68 (PSMA-11). We aimed to evaluate its positivity rate and impact in patients presenting biochemical recurrence of prostate cancer whose (18)F-fluorocholine (FCH) PET/CT was non-contributive. PATIENTS AND METHOD: Patients were prospectively included between April and December 2016. PET/CT was performed 60min after injection of 2MBq/kg of body mass of (68)Ga-PSMA-11...
June 2017: Progrès en Urologie
https://www.readbyqxmd.com/read/28551611/-68-ga-psma-pet-ct-has-a-role-in-detecting-prostate-cancer-lesions-in-patients-with-recurrent-disease
#7
REVIEW
Claire Fitzpatrick, Olwyn Lynch, Laure Marignol
BACKGROUND/AIM: Early detection of recurrent πrostate cancer (PCa) lesions is paramount to allow patients to avail of localised salvage therapy options. The most significant reason for failure of salvage therapy is undetected metastatic disease. This demonstrates the need for a more accurate monitoring tool. The prostate-specific membrane antigen (PSMA) is increasingly investigated as a novel tracer for gallium 68 PET/CT to detect PCa lesions in patients with recurrent disease. MATERIALS AND METHODS: The Embase, Pubmed and the Cochrane databases were searched to identify studies investigating the accuracy of (68)Ga-PSMA-PET/CT in detecting PCa lesions...
June 2017: Anticancer Research
https://www.readbyqxmd.com/read/28533641/image-findings-of-a-rare-case-of-neuroendocrine-tumor-metastatic-to-orbital-extraocular-muscle-in-gallium-68-dotanoc-positron-emission-tomography-computed-tomography-and-therapy-with-lutetium-177-dotatate
#8
Koramadai Karuppusamy Kamaleshwaran, Jephy Joseph, Indra Upadhya, Ajit Sugunan Shinto
Metastatic tumor is one of several etiologies of space-occupying masses in the orbit that accounts for 1-13% of all orbital masses. In the adult patient population, breast cancer is the most common tumor to metastasize to the orbit, followed by metastasis from the lung, prostate, and gastrointestinal tract. Carcinoid tumors are rare neuroendocrine neoplasms derived from enterochromaffin cells, which are found primarily in the gastrointestinal tract and bronchial tree. Liver metastases are the classic presentation of distant disease...
April 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28533638/clinical-utility-of-gallium-68-psma-pet-ct-scan-for-prostate-cancer
#9
Kumaraswamy G Kallur, Prashanth G Ramachandra, Krishnappa Rajkumar, Shivakumar S Swamy, Indiresh Desai, Raghavendra M Rao, Shekhar Gowda Patil, P S Sridhar, Nagaraj Madhusudhan, Raghunath S Krishnappa, Veerendra Bhadrasetty, Hemantha M Kumara, S D Santhosh, Basavalingaiah S Ajaikumar
BACKGROUND: Prostate cancer is biologically and clinically a heterogeneous disease that makes imaging evaluation challenging. One of the important challenges in this cancer is to detect recurrent disease. Biochemical response using Prostate Specific Antigen (PSA) and Imaging using several PET tracers have poor sensitivity and specificity. Therefore, we analyse the role of Ga68-PSMA (Prostate Specific Membrane Antigen) imaging in prostate cancer, which is a new PET tracer. METHODS: In this study, we evaluated PET scans of 262 patients with diagnosis of prostate cancer...
April 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28511061/uptake-of-ga-curcumin-derivatives-in-different-cancer-cell-lines-toward-the-development-of-new-potential-68-ga-labelled-curcuminoids-based-radiotracers-for-tumour-imaging
#10
Sara Rubagotti, Stefania Croci, Erika Ferrari, Giulia Orteca, Michele Iori, Pier C Capponi, Annibale Versari, Mattia Asti
Thanks to the ability to suppress the proliferation and to kill tumour cells, several studies have shown the anti-cancer effects of curcumin (CUR) and its derivatives, i.e. diacetylcurcumin (DAC) and bis-dehydroxycurcumin (bDHC). This study is focused onto the development of curcuminoid complexes with gallium-68 employed as potential new radio-labelled probes to detect neoplastic tissues through imaging techniques such as positron emission tomography. To this purpose, the uptake of three Ga-curcuminoid complexes, namely Ga(CUR)2(+), Ga(DAC)2(+), Ga(bDHC)2(+), by various tumour cell lines was compared with the uptake of the same compounds by normal human lymphocytes by flow cytometry using the intrinsic fluorescence of the curcuminoids...
May 10, 2017: Journal of Inorganic Biochemistry
https://www.readbyqxmd.com/read/28474140/comparison-of-psma-hbed-and-psma-i-t-as-diagnostic-agents-in-prostate-carcinoma
#11
Michael McCarthy, Tiffany Langton, Divesh Kumar, Andrew Campbell
PURPOSE: Gallium(68)-labelled prostate-specific membrane antigen (PSMA) radiopharmaceuticals can be used to detect prostate cancer (PCa) cells due the their over expression of PSMA. The (68)Ga HBED-PSMA (PSMA-HBED) ligand has been most widely used and can be considered the current gold standard agent. Further PSMA ligands based on the DOTAGA and DOTA conjugates have more recently been developed. These agents (PSMA-I&T and PSMA-617) have potential theranostic capabilities as they can be conjugated with therapeutic radioisotopes...
August 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28462989/developing-targeted-hybrid-imaging-probes-by-chelator-scaffolding
#12
Dominik Summer, Leo Grossrubatscher, Milos Petrik, Tereza Michalcikova, Zbynek Novy, Christine Rangger, Maximilian Klingler, Hubertus Haas, Piriya Kaeopookum, Elisabeth von Guggenberg, Roland Haubner, Clemens Decristoforo
Positron emission tomography (PET) as well as optical imaging (OI) with peptide receptor targeting probes have proven their value for oncological applications but also show restrictions depending on the clinical field of interest. Therefore, the combination of both methods, particularly in a single molecule, could improve versatility in clinical routine. This proof of principle study aims to show that a chelator, Fusarinine C (FSC), can be utilized as scaffold for novel dimeric dual-modality imaging agents...
June 21, 2017: Bioconjugate Chemistry
https://www.readbyqxmd.com/read/28462171/multiple-recurrent-paraganglioma-in-a-pediatric-patient-with-germline-sdh-b-mutation
#13
Aidan McGowan, Julie Y An, Sally Tanakchi, Mahir Maruf, Akhil Muthigi, Arvin George, Daniel Su, Maria J Merino, W Marston Linehan, Shawna L Boyle, Adam R Metwalli
Magnetic Resonance Imaging (MRI) and fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) are recognized approaches for locating paragangliomas. Recently, gallium-68 DOTA-octreotate (DOTATATE) scans have shown promise detecting neuroendocrine tumors missed by FDG-PET and MRI. 13-year-old male with SDH-B mutation presented with symptoms of paraganglioma and elevated catecholamines. MRI did not demonstrate the T2 hyper intense signal typical of paraganglioma and pheochromocytoma; FDG-PET scan did not reveal increased foci of uptake...
July 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28408526/-68-ga-or-18-f-for-prostate-cancer-imaging
#14
Claudia Kesch, Clemens Kratochwil, Walter Mier, Klaus Kopka, Frederik L Giesel
No abstract text is available yet for this article.
May 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28385306/detection-of-atherosclerotic-inflammation-by-68-ga-dotatate-pet-compared-to-18-f-fdg-pet-imaging
#15
COMPARATIVE STUDY
Jason M Tarkin, Francis R Joshi, Nicholas R Evans, Mohammed M Chowdhury, Nichola L Figg, Aarti V Shah, Lakshi T Starks, Abel Martin-Garrido, Roido Manavaki, Emma Yu, Rhoda E Kuc, Luigi Grassi, Roman Kreuzhuber, Myrto A Kostadima, Mattia Frontini, Peter J Kirkpatrick, Patrick A Coughlin, Deepa Gopalan, Tim D Fryer, John R Buscombe, Ashley M Groves, Willem H Ouwehand, Martin R Bennett, Elizabeth A Warburton, Anthony P Davenport, James H F Rudd
BACKGROUND: Inflammation drives atherosclerotic plaque rupture. Although inflammation can be measured using fluorine-18-labeled fluorodeoxyglucose positron emission tomography ([(18)F]FDG PET), [(18)F]FDG lacks cell specificity, and coronary imaging is unreliable because of myocardial spillover. OBJECTIVES: This study tested the efficacy of gallium-68-labeled DOTATATE ((68)Ga-DOTATATE), a somatostatin receptor subtype-2 (SST2)-binding PET tracer, for imaging atherosclerotic inflammation...
April 11, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28349676/flourodeoxyglucose-positron-emission-tomography-scan-may-be-helpful-in-the-case-of-ductal-variant-prostate-cancer-when-prostate-specific-membrane-antigen-ligand-positron-emission-tomography-scan-is-negative
#16
Louise M McEwan, David Wong, John Yaxley
Gallium-68 prostate specific membrane antigen ligand (Ga-68 PSMA) positron emission tomography/computed tomography (PET/CT) scanning is emerging as a useful imaging modality for the staging of suspected and known recurrent or metastatic prostate cancer and in staging of newly diagnosed higher grade prostate cancer. However, we have observed at our institution that in some cases of the more aggressive ductal variant, Ga-68 PSMA uptake has sometimes been poor compared with prominent 18-flourodeoxyglucose (F-18 FDG) avidity seen in F-18 FDG PET/CT, which would suggest that FDG PET/CT scans are important in staging of ductal pattern prostate cancer...
March 28, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/28332878/three-diagnoses-on-one-gallium-68-dotatate-scan
#17
Run Yu, Andrew Quon, J Randolph Hecht
No abstract text is available yet for this article.
March 23, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28316937/metastasectomy-of-abdominal-wall-lesions-due-to-prostate-cancer-detected-through-pet-ct-gallium-68-pmsa-first-case-report
#18
Claudia Ochoa, Angie Ramirez, Rodolfo Varela, Fabian Godoy, Rafael Vargas, Jorge Forero, Andres Rojas, Carmen Roa, Carlos Céspedes, Jose Ramos, Marino Cabrera, Andres Calderon
Introducing the topic of abdominal wall metastasis secondary to prostate cancer with a reminder of the disease's rarity, being the first published case. This article is about a 66 year old patient diagnosed with prostate cancer [cT2aNxMx iPSA: 5,6 ng/ml Gleason 3+3, (Grade 1 Group)], treated with radical prostatectomy as well as accompanied with amplified pelvic lymphadenectomy, who subsequently presented metastatic lesions to the abdominal wall diagnosed with PET/CT Gallium 68-PMSA technique and treated with abdominal metastasectomy with adequate short term results...
May 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28267455/gallium-68-prostate-specific-membrane-antigen-pet-imaging
#19
REVIEW
Michael S Hofman, Amir Iravani
The role of gallium-68 ((68)Ga) prostate-specific membrane antigen (PSMA) PET imaging is evolving and finding its place in the imaging armamentarium for prostate cancer (PCa). Despite the progress of conventional imaging strategies, significant limitations remain, including identification of small-volume disease and assessment of bone. Clinical studies have demonstrated that (68)Ga-PSMA is a promising tracer for detection of PCa metastases, even in patients with low prostate-specific antigen. To provide an accurate interpretation of (68)Ga-PSMA PET/computed tomography, nuclear medicine specialists and radiologists should be familiar with physiologic (68)Ga-PSMA uptake, common variants, patterns of locoregional and distant spread of PCa, and inherent pitfalls...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28267450/imaging-of-prostate-cancer-using-gallium-68-labeled-bombesin
#20
REVIEW
Ida Sonni, Lucia Baratto, Andrei Iagaru
Nuclear medicine can play an important role in evaluating prostate cancer combining anatomical and functional information with hybrid techniques. Various PET radiopharmaceuticals have been used for targeting specific biological markers in prostate cancer. Research is ideally oriented towards the development of radiopharmaceuticals targeting antigens overexpressed in prostate cancer, as opposed to normal prostate tissue. In this regard, gastrin-releasing peptide receptors (GRPR) are excellent candidates. Bombesin analogues targeting the GRPR have been investigated...
April 2017: PET Clinics
keyword
keyword
56422
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"